Derniers articles

Surrogate endpoints for overall survival in lung cancer trials: a review.

ABSTRACTIntroduction: Intermediate endpoints are often used as primary endpoints instead of overall survival (OS) in...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Expert Review of Anticancer Therapy

Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study

Background:To assess the efficacy of a patient educational program built according to guidelines that aims at reducing...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : British Journal of Cancer

Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial

Background Nab-paclitaxel plus gemcitabine has become a standard treatment regimen in patients with metastatic...

Posté par : Mme. Aurélia MEURISSE, Pr. Franck BONNETAIN
Nom de la revue : Lancet Gastroenterology Hepatology

Predictors of long-term functional outcome and health-related quality of life after out-of-hospital cardiac arrest

BackgroundEven if a large majority of out-of-hospital cardiac arrest (OHCA) survivors appear to have a good neurological...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Resuscitation

Évaluation de la qualité de vie relative à la santé suite au diagnostic de cancer

La mesure de la qualité de vie relative à la santé des personnes traitées pour un cancer se développe. Ce nouvel...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY, Mme. Joëlle FRITZSCH,
Nom de la revue : La revue de l'infirmière

Parcours de soins des patients atteints de cancer du pancréas métastatique en pratique courante en France : résultats de l’enquête nationale REPERE

RésuméLes données dans la littérature concernant les parcours de soins des patients atteints de cancer du pancréas...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Bulletin du Cancer

Evaluation of efficacy and efficiency of a pragmatic intervention by a social worker to support informal caregivers of elderly patients (The ICE Study): study protocol for a randomized controlled trial

Background: Medical progress and the lifestyle modification have prolonged life expectancy, despite the development of...

Posté par : , Pr. Franck BONNETAIN
Nom de la revue : Trials

Development and validation of the FRAGIRE tool for assessment an older person’s risk for frailty

AbstractBackground: Frailty is highly prevalent in elderly people. While significant progress has been made to...

Posté par : Dr. Dewi VERNEREY, Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : BMC Geriatrics

Additive value of pre-operative and one-month post-operative lymphocyte count for death-risk stratification in patients with resectable pancreatic cancer: a multicentric study

AbstractBackground: Pancreatic adenocarcinoma (PDAC) incidence is increasing worldwide. Several studies have shown...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : BMC Cancer

Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards

Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Lancet Oncology

Docetaxel, Cisplatin, and 5-Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma

Docetaxel, cisplatin, and 5-fluorouracil (DCF) significantly improved overall survival in metastatic gastroesophageal...

Posté par : Pr. Franck BONNETAIN, Dr. Sophie PAGET-BAILLY
Nom de la revue : Cancer Medecine

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

Background: The management of locally advanced pancreatic cancer (LAPC) patients remains controversial. Better...

Posté par : Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Nom de la revue : British Journal of Cancer

Prognostic value of baseline seric Syndecan-1 in initially unresectable metastatic colorectal cancer patients: a simple biological score

In first-line metastatic colorectal cancer (mCRC), baseline prognostic factors allowing death risk and treatment...

Posté par : Dr. Dewi VERNEREY, Pr. Franck BONNETAIN
Nom de la revue : International Journal of Cancer

Surrogate end points for overall survival in breast cancer trials: A review.

Our aim was to review the studies which assessed potential surrogate endpoints for overall survival (OS) in breast...

Posté par : Pr. Franck BONNETAIN,
Nom de la revue : Breast

Health-related quality of life in elderly patients with advanced non-small cell lung cancer comparing carboplatin and weekly paclitaxel doublet chemotherapy with monotherapy.

In the Intergroupe Francophone de Cancérologie Thoracique 0501 trial the carboplatinpaclitaxel chemotherapy increased...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : European Respiratory Journal

Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma

Background: Even though the perioperative chemotherapy improves the overall survival (OS) compared to surgery alone in...

Posté par : Dr. Sophie PAGET-BAILLY, , Pr. Franck BONNETAIN
Nom de la revue : European Journal of Surgical Oncology

Prognostic value of health-related quality of life for death risk stratification in patients with unresectable glioblastoma

AbstractGlioblastoma is the most common malignant brain tumor in adults. Baselinehealth-relatedquality of life (HRQoL)...

Posté par : , Dr. Dewi VERNEREY, , Pr. Franck BONNETAIN
Nom de la revue : Cancer Medicine

Time to Definitive Health-Related Quality of Life Score Deterioration in Patients with Resectable Metastatic Colorectal Cancer Treated with FOLFOX4 versus Sequential Dose-Dense FOLFOX7 followed by FOLFIRI: The MIROX Randomized Phase III Trial

PurposeWe previously showed that a sequential chemotherapy with dose-dense oxaliplatin (FOLFOX7)and irinotecan (FOLFIRI;...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : PLOS ONE

An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma

OBJECTIVES: The objective of this study was to explore the association between health-related quality of life (HRQoL)...

Posté par : , Pr. Franck BONNETAIN
Nom de la revue : BMJ Open

09 Mai, 2016

Impact of pharmaceutical intervention on quality of life and coping strategies in patients with haematological malignancies

OBJECTIVES: We conducted a prospective study approved by the local ethics committee to determine the impact of a...

Posté par : Pr. Franck BONNETAIN
Nom de la revue : Annales pharmaceutiques françaises